Sirna Therapeutics (RNAI) Reports a Q3 Loss
More News related to RNAI
- 52-Week Highs of Note
- Merck (MRK) and Sirna (RNAI) Merck Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of Sirna by Merck
- Sirna Therapeutics (RNAI) Reports a Q3 Loss
- HealthCor Management Sends New Letter to ICOS (ICOS) Opposing Eli Lilly Takeover
- Rodman & Renshaw Bullish on Bioenvision (BIVN), Says Stock Does Not Reflect Clofarabine or Buyout
More News related to Earnings
- Dow Chem. (DOW) Subsidiary to Acquire Hyland Seeds; Cowan to Remain General Manager
- Windstream (WIN) to Acquire Iowa Telecom (IWA) for 0.804/Shares Plus $7.90 in Cash; Deal Valued at $1.1B
- Interactive Data Corp. (IDC) to Acquire Dow Jones OFS Data and Tools Assets
- Green Mountain (GMCR) Confirms $32/Share Bid for Diedrich Coffee (DDRX)
- Rockwell Collins (COL) To Acquire Air Routing Group for Undisclosed Amount
Sirna Therapeutics Inc. (Nasdaq: RNAI) reports a Q3 loss of $0.13 compared to a net loss of $0.08 per share, for the same period in 2005.
Revenues for the third quarter of 2006 were $2.0 million compared to $1.9 million in the third quarter of 2005. Deferred revenues from collaboration partners, included on the balance sheet at September 30, 2006, were $9.7 million.
Related Categories
EarningsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
